Industry-Leading Content Supply Chain
At Boehringer Ingelheim, Dr. Kurr built what external benchmarking studies recognized as "one of the leading content supply chains in the industry." The operation encompassed end-to-end content creation, review, approval, and distribution across all global markets - supported by a Digital Content Factory (offshore production center in India), a Creative Factory launched in 2023, and a Global Services Operations Team that ensured quality and consistency at scale.
Omnichannel & Go-to-Market Transformation
Dr. Kurr led the strategic partnership with Indegene to transform Boehringer Ingelheim's go-to-market operations. As he noted: "Over the last 3 years, Indegene has helped us transform our go-to-market operations and enable better physician and patient engagement via more agile, data-driven, omnichannel ways." This transformation covered the full spectrum of commercial and medical engagement - from HCP interactions to patient-facing content.
Fractional CCO at Lemna Bio
Building on this track record, Dr. Kurr now serves as Fractional Chief Commercial Officer at Lemna Bio, a computational drug design company in Lausanne. Here he brings his operational playbook to an early-stage biotech context - developing commercial strategy and partnership frameworks for a company pioneering complex mini-protein therapeutics.